About: The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
Creator	Hou, Yixuan Sette, Alessandro Baric, Ralph Weiss, Susan Edupuganti, Srilatha De Silva, Aravinda Jadi, Ramesh Rouphael, Nadine Schmitz, John Collins, Matthew Martinez, David Premkumar, Lakshmanane Scherer, Erin Tse, Longping Weiskopf, Daniela Bartelt, Luther Cornaby, Caleb Edwards, Caitlin Margolis, David Markmann, Alena Park, Yara Raut, Rajendra Segovia-Chumbez, Bruno Weimer, Eric
Source	Medline; PMC
abstract	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first emerged in late 2019 is responsible for a pandemic of severe respiratory illness. People infected with this highly contagious virus can present with clinically inapparent, mild, or severe disease. Currently, the virus infection in individuals and at the population level is being monitored by PCR testing of symptomatic patients for the presence of viral RNA. There is an urgent need for SARS-CoV-2 serologic tests to identify all infected individuals, irrespective of clinical symptoms, to conduct surveillance and implement strategies to contain spread. As the receptor binding domain (RBD) of the spike protein is poorly conserved between SARS-CoVs and other pathogenic human coronaviruses, the RBD represents a promising antigen for detecting CoV-specific antibodies in people. Here we use a large panel of human sera (63 SARS-CoV-2 patients and 71 control subjects) and hyperimmune sera from animals exposed to zoonotic CoVs to evaluate RBD's performance as an antigen for reliable detection of SARS-CoV-2-specific antibodies. By day 9 after the onset of symptoms, the recombinant SARS-CoV-2 RBD antigen was highly sensitive (98%) and specific (100%) for antibodies induced by SARS-CoVs. We observed a strong correlation between levels of RBD binding antibodies and SARS-CoV-2 neutralizing antibodies in patients. Our results, which reveal the early kinetics of SARS-CoV-2 antibody responses, support using the RBD antigen in serological diagnostic assays and RBD-specific antibody levels as a correlate of SARS-CoV-2 neutralizing antibodies in people.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.1126/sciimmunol.abc8413
bibo:pmid	32527802
has license	cc-by
sha1sum (hex)	0bc74879d3ef31cdc5f6ab2000190d2874a0553e
schema:url	https://doi.org/10.1126/sciimmunol.abc8413
resource representing a document's title	The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
has PubMed Central identifier	PMC7292505
has PubMed identifier	32527802
schema:publication	Sci Immunol
resource representing a document's body	covid:0bc74879d3ef31cdc5f6ab2000190d2874a0553e#body_text
is schema:about of	named entity 'People' named entity 'RBD' named entity 'responsible' named entity 'Our' named entity 'support' named entity 'reliable' named entity 'detection' named entity 'antibodies' named entity 'SARS' named entity 'PANEL' named entity 'USE' named entity 'PATIENTS' named entity 'SUPPORT' named entity 'SEROLOGICAL' named entity 'BINDING' named entity 'CONTROL' named entity 'INDUCED' named entity 'ZOONOTIC' named entity 'SPECIFIC' named entity 'SYMPTOMATIC' covid:arg/0bc74879d3ef31cdc5f6ab2000190d2874a0553e named entity 'SARS-CoV-2' named entity 'promising' named entity 'patients' named entity 'contagious' named entity 'reveal' named entity 'individuals' named entity 'surveillance' named entity 'antibodies' named entity 'serologic tests' named entity 'SARS-CoV-2' named entity 'levels' named entity 'symptoms' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'RBD' named entity 'SARS' named entity 'antibodies' named entity 'antibodies' named entity 'kinetics' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'neutralizing antibodies' named entity 'RBD' named entity 'neutralizing antibodies' named entity 'correlation' named entity 'SARS-CoV-2' named entity 'PCR testing' named entity 'large' named entity 'secondary antibody' named entity 'IgA' named entity 'SARS-CoV-2' named entity 'La Jolla Institute for Immunology' named entity 'MERS CoV' named entity 'SARS' named entity 'U.S.' named entity 'PCR' named entity 'Molecular Graphics'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software